Compare DAICW & GRMLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAICW | GRMLW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 68 | 5 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2022 |
| Metric | DAICW | GRMLW |
|---|---|---|
| Price | $0.02 | $0.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.1K | ★ 23.6K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.10 |
| 52 Week High | $0.19 | $0.37 |
| Indicator | DAICW | GRMLW |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 59.50 |
| Support Level | $0.02 | $0.13 |
| Resistance Level | $0.04 | $0.26 |
| Average True Range (ATR) | 0.00 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 74.47 | 73.91 |
CID Holdco Inc helps businesses digitally transform their operations using IoT and AI technology. Its main focus includes areas such as Industrial IoT, Indoor & Outdoor tracking with seamless transitions, Passive RFID (including Bluetooth and 5G), Collision Avoidance, real-time locating system, Dolly Management, and related supported software applications. The company is the developer of an asset tracking platform intended to push the limits of real-time precision-based location technology. Through its technological solutions, the Company serves multiple industries including Aviation, Construction, Delivery, Military, Mining, Retail, Sea Ports, Medical Logistics, Warehousing and Manufacturing.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.